CN115698052A - 白介素2突变体及其用途 - Google Patents

白介素2突变体及其用途 Download PDF

Info

Publication number
CN115698052A
CN115698052A CN202180021848.0A CN202180021848A CN115698052A CN 115698052 A CN115698052 A CN 115698052A CN 202180021848 A CN202180021848 A CN 202180021848A CN 115698052 A CN115698052 A CN 115698052A
Authority
CN
China
Prior art keywords
mutation
mutein
sequence
mutations
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021848.0A
Other languages
English (en)
Chinese (zh)
Inventor
何开杰
付凤根
周帅祥
伍伟伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of CN115698052A publication Critical patent/CN115698052A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180021848.0A 2020-03-19 2021-03-19 白介素2突变体及其用途 Pending CN115698052A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010197740 2020-03-19
CN2020101977404 2020-03-19
CN2021102665495 2021-03-11
CN202110266549 2021-03-11
PCT/CN2021/081840 WO2021185361A1 (zh) 2020-03-19 2021-03-19 白介素2突变体及其用途

Publications (1)

Publication Number Publication Date
CN115698052A true CN115698052A (zh) 2023-02-03

Family

ID=77770497

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021848.0A Pending CN115698052A (zh) 2020-03-19 2021-03-19 白介素2突变体及其用途

Country Status (9)

Country Link
US (1) US20230145766A1 (https=)
EP (1) EP4122952A4 (https=)
JP (1) JP2023518434A (https=)
KR (1) KR20220155316A (https=)
CN (1) CN115698052A (https=)
AU (1) AU2021239225B2 (https=)
CA (1) CA3175717A1 (https=)
TW (1) TWI790573B (https=)
WO (1) WO2021185361A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117116336A (zh) * 2023-10-18 2023-11-24 深圳新锐基因科技有限公司 基于蛋白分子内部原子波动改善蛋白结构柔性弱点的方法和装置
WO2024183527A1 (en) * 2023-03-09 2024-09-12 Beijing Mabworks Biotech Co., Ltd Il-2 variants and uses thereof
WO2024193670A1 (zh) * 2023-03-21 2024-09-26 弗维塔生物制药（新加坡）有限公司 抗pd-1与突变il-2免疫缀合物制剂

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020057646A1 (zh) 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
EP3854805A4 (en) 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
AU2021237518B2 (en) * 2020-03-19 2024-08-15 Fortvita Biologics (Singapore) Pte.Ltd. Interleukin-2 mutant and use thereof
CN114380919B (zh) * 2020-10-18 2024-06-25 北京志道生物科技有限公司 经修饰的il-2分子及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20240082364A (ko) * 2021-09-22 2024-06-10 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 인터루킨-2 돌연변이 및 이의 융합 단백질
WO2023169524A1 (zh) * 2022-03-10 2023-09-14 广东菲鹏制药股份有限公司 白细胞介素2突变体以及含有其的复合物
CA3259108A1 (en) 2022-06-16 2023-12-21 Cephalon Llc Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses
CN119365482A (zh) * 2022-06-17 2025-01-24 舒泰神（北京）生物制药股份有限公司 白介素-2(il-2)突变体及其用途
TW202402784A (zh) * 2022-07-06 2024-01-16 中國商科望（上海）生物醫藥科技有限公司 Il2突變蛋白及其用途
US20250195677A1 (en) * 2023-12-19 2025-06-19 Cephalon Llc Uses for attenuated il-2 immunoconjugates
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0485497A1 (en) * 1989-08-02 1992-05-20 Seragen, Incorporated Il-2 deletion mutants
US20060160187A1 (en) * 2004-03-05 2006-07-20 Chiron Corporation Combinatorial interleukin-2 muteins
CN103492411A (zh) * 2011-02-10 2014-01-01 罗切格利卡特公司 突变体白介素-2多肽
WO2019246404A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP3854805A4 (en) * 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
AU2021237518B2 (en) * 2020-03-19 2024-08-15 Fortvita Biologics (Singapore) Pte.Ltd. Interleukin-2 mutant and use thereof
KR20240082364A (ko) * 2021-09-22 2024-06-10 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 인터루킨-2 돌연변이 및 이의 융합 단백질

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0485497A1 (en) * 1989-08-02 1992-05-20 Seragen, Incorporated Il-2 deletion mutants
US20060160187A1 (en) * 2004-03-05 2006-07-20 Chiron Corporation Combinatorial interleukin-2 muteins
CN103492411A (zh) * 2011-02-10 2014-01-01 罗切格利卡特公司 突变体白介素-2多肽
WO2019246404A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CN112638406A (zh) * 2018-06-22 2021-04-09 科优基因公司 白介素-2变体及其使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEIWEI WU等: "IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells", 《NATURE CANCER》, vol. 4, 7 August 2023 (2023-08-07), pages 1309 - 1325, XP093149895, DOI: 10.1038/s43018-023-00612-0 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024183527A1 (en) * 2023-03-09 2024-09-12 Beijing Mabworks Biotech Co., Ltd Il-2 variants and uses thereof
WO2024193670A1 (zh) * 2023-03-21 2024-09-26 弗维塔生物制药（新加坡）有限公司 抗pd-1与突变il-2免疫缀合物制剂
CN117116336A (zh) * 2023-10-18 2023-11-24 深圳新锐基因科技有限公司 基于蛋白分子内部原子波动改善蛋白结构柔性弱点的方法和装置
CN117116336B (zh) * 2023-10-18 2024-01-23 深圳新锐基因科技有限公司 基于内部原子波动改善蛋白结构柔性弱点的方法和装置

Also Published As

Publication number Publication date
US20230145766A1 (en) 2023-05-11
KR20220155316A (ko) 2022-11-22
EP4122952A4 (en) 2024-05-29
TW202144392A (zh) 2021-12-01
AU2021239225A1 (en) 2022-10-13
JP2023518434A (ja) 2023-05-01
EP4122952A1 (en) 2023-01-25
WO2021185361A1 (zh) 2021-09-23
AU2021239225B2 (en) 2024-08-15
TWI790573B (zh) 2023-01-21
CA3175717A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
CN115698052A (zh) 白介素2突变体及其用途
CN114901679B (zh) 全新被掩蔽的细胞因子及其应用
AU2002210918B2 (en) Degraded agonist antibody
CN112105634A (zh) 新型白介素2及其用途
US20220073588A1 (en) TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS
KR102609197B1 (ko) 인터류킨 15 단백질 복합체 및 그의 용도
EP2027153B1 (en) Dimeric molecular complexes
US8586039B2 (en) Degraded TPO agonist antibody
US20090311718A1 (en) Degraded agonist antibody
JP2025069262A (ja) 受容体対形成に関連する組成物および方法
JP2022553464A (ja) 多重特異性抗体とその製造方法および使用
CN111699201B (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
CN113195534A (zh) 包含il-15/il-15ra fc融合蛋白和lag-3抗原结合结构域的靶向lag-3的异源二聚体融合蛋白
CN104640561A (zh) 包含轻链和重链的选择性配对的免疫球蛋白构建体
WO2011079308A2 (en) Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
RU2295537C2 (ru) Модифицированное агонистическое антитело
JPWO2021185361A5 (https=)
JPWO2020172605A5 (https=)
US20240262931A1 (en) Precursor proteins and kit for targeted therapy
JPWO2022200525A5 (https=)
US20250333507A1 (en) Fusion protein of anti-tigit antibody and il2 or variant thereof, and application thereof
JP7398677B2 (ja) ウテログロビンを構造基盤とする二重特異性ポリペプチド
JP7829127B2 (ja) 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質
CN115819605B (zh) 一种连接抗体的抗原结合功能域的方法及其应用
CN113912735B (zh) 多肽二聚体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088124

Country of ref document: HK